COMPANIES COVERED
NovartisDownload FREE Report Sample
Download Free sampleImatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases.
Imatinib Drug Market contains market size and forecasts of Imatinib Drug in global, including the following market information:
Global Imatinib Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Imatinib Drug Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Imatinib Drug companies in 2021 (%)
The global Imatinib Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Tablets Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Imatinib Drug include Novartis, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals, Actavis Generics, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Cipla Inc. and Apotex Inc. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Imatinib Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Imatinib Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Imatinib Drug Market Segment Percentages, by Type, 2021 (%)
Tablets
Capsules
Global Imatinib Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Imatinib Drug Market Segment Percentages, by Application, 2021 (%)
Chronic Myelogenous Leukemia
Gastrointestinal Stromal Tumors
Others
Global Imatinib Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Imatinib Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Imatinib Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Imatinib Drug revenues share in global market, 2021 (%)
Key companies Imatinib Drug sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Imatinib Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Glenmark Pharmaceuticals Ltd.
Sun Pharmaceuticals
Actavis Generics
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Cipla Inc.
Apotex Inc.
Mylan Pharms Inc.
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
